Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium
Year: 2021
Type: conference-abstract
Source: Blood
Institutions: Chulalongkorn University, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, University of Minnesota, OHSU Knight Cancer Institute, University of Kansas Medical Center, The University of Texas MD Anderson Cancer Center, University of Chicago, University of Chicago Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3213110313